



May 14, 2026

Company Name    LinqMed Inc.  
Representative    Yukie Yoshii, President and CEO

## **LinqMed Selected for the UK Program Following the Pitch Contest at the Nakanoshima Qross Innovation Challenge**

LinqMed Inc. (President and CEO: Yukie Yoshii; headquarters: Chiba City; hereinafter “LinqMed” or “the Company”) is pleased to announce that, following the pitch contest held as part of the “Nakanoshima Qross Innovation Challenge” organized by Osaka Prefecture, the Company has been selected to participate in the UK Immersion Program.

The “Nakanoshima Qross Innovation Challenge” is a selective pitch event in which 16 promising startups in the life sciences field, each aiming for global expansion, present the results of an approximately six-month acceleration program. The purpose of the event is to create a “challenge platform” that identifies promising startups from Osaka’s Nakanoshima area that are ready to take on global markets and connects them to their next growth opportunities. At the pitch contest held on May 12, 2026, the Company’s next-generation radiopharmaceutical utilizing the radioisotope copper-64 ( $^{64}\text{Cu}$ ), which can be used for both cancer diagnosis and therapy—an innovative “Visible” cancer radiotherapeutics—was recognized for its potential for overseas expansion, resulting in the Company’s selection for the UK Immersion Program.



### **Comment from Yukie Yoshii, President and CEO of LinqMed Inc.:**

*“We are deeply honored to have the opportunity to participate in the UK Immersion Program. We are delighted that our business achievements to date and our strategy for overseas expansion have been recognized, and we hope to use this opportunity as a foothold for expansion into the United Kingdom and other European countries. LinqMed is developing therapeutic and diagnostic agents for cancer using <sup>64</sup>Cu, a radioisotope of copper. We will continue to devote ourselves to expanding our innovative “Visible” cancer radiotherapeutics globally and to helping as many patients around the world as possible.”*



### **About the Nakanoshima Qross Innovation Challenge**

The “NQ Global Startup Gateway,” organized by Osaka Prefecture, is a global, implementation-oriented acceleration and co-creation program that uses Nakanoshima Qross as its starting point to guide future medical startups toward global standards. This event is a selective pitch event in which 16 promising startups in the life sciences field, each aiming for global expansion, present the results of an approximately six-month acceleration program. Through the pitch selection process, three companies are selected to advance to the next phase (Phase 2). Selected companies are given the opportunity to participate in a UK Immersion Program that includes executive mentoring and connections with the UK ecosystem.

<https://www.link-j.org/event/article-45665.html>

<https://nq-gateway.jp/archives/574>

End

## **About LinqMed**

LinqMed Inc. is an R&D start-up company developing radiopharmaceuticals to provide innovative “visible” anti-cancer treatments to patients. Our mission is “Link for Life -Linking Innovative Science and Medicine for Your Health and Happiness”. LinqMed Inc. has been launched as a certified venture company of the National Institutes for Quantum Sciences and Technology (QST). We are developing radiopharmaceuticals using a copper radioisotope  $^{64}\text{Cu}$ , which can be used for diagnosis and therapy, simultaneously.

URL : <https://linqmed.net/>

### **Inquiries:**

**LinqMed Inc.**

Email: [linqmed@linqmed.co.jp](mailto:linqmed@linqmed.co.jp)